214 related articles for article (PubMed ID: 30952104)
1. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
[TBL] [Abstract][Full Text] [Related]
3. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.
Meckley LM; Wu Y; Ito D; Berner T; McCoy B; Yel L
BMC Immunol; 2020 May; 21(1):24. PubMed ID: 32366233
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases.
Navarro-Mora G; Alberti JJ; Mondou E; Vilardell D; Vicente Torres J; Ayguasanosa J; Páez A
Int Immunopharmacol; 2022 Mar; 104():108472. PubMed ID: 35008008
[TBL] [Abstract][Full Text] [Related]
5. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Li Z; McCoy B; Engl W; Yel L
J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
[TBL] [Abstract][Full Text] [Related]
6. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
7. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
[TBL] [Abstract][Full Text] [Related]
8. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
Shapiro R
Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
[TBL] [Abstract][Full Text] [Related]
10. Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
Luo D; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
Clin Ther; 2020 Jan; 42(1):196-209.e5. PubMed ID: 31910997
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies - real-world data from the IG TATRY study.
Heropolitańska-Pliszka E; Pac M; Pietrucha B; Machura E; Pukas-Bochenek A; Chrobak E; Bień E; Malanowska M; Pituch-Noworolska A; Drygała S; Kamieniak M; Kasprzak J; Mach-Tomalska M
Expert Rev Clin Immunol; 2023; 19(10):1281-1291. PubMed ID: 37489744
[TBL] [Abstract][Full Text] [Related]
12. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants.
Meckley LM; Wu Y; Tzivelekis S; Gandhi V; Gladiator A
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):568-574.e1. PubMed ID: 34224864
[TBL] [Abstract][Full Text] [Related]
13. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
16. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
Berger M
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.
Sidhu J; Rojavin M; Pfister M; Edelman J
Biol Ther; 2014 Dec; 4(1-2):41-55. PubMed ID: 25118975
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.
Zhang Y; Baheti G; Chapdelaine H; Hofmann J; Rojavin M; Tortorici M; Haddad E
Int Immunopharmacol; 2020 Apr; 81():106005. PubMed ID: 31806567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]